Quad Cities Investment Group LLC Buys Shares of 399 Eli Lilly and Company (NYSE:LLY)

Quad Cities Investment Group LLC bought a new stake in Eli Lilly and Company (NYSE:LLYFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 399 shares of the company’s stock, valued at approximately $250,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Fairfield Bush & CO. bought a new position in Eli Lilly and Company during the 1st quarter worth $107,000. Roundview Capital LLC increased its stake in shares of Eli Lilly and Company by 2.6% in the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $210,000. NewEdge Advisors LLC increased its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $561,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total value of $21,821,453.78. Following the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Truist Financial raised their target price on Eli Lilly and Company from $650.00 to $850.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Bank of America raised their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Finally, Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $677.62.

View Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Trading Down 0.9 %

Shares of Eli Lilly and Company stock opened at $754.17 on Monday. The stock has a fifty day simple moving average of $708.78 and a 200 day simple moving average of $625.80. Eli Lilly and Company has a 12-month low of $323.26 and a 12-month high of $800.78. The company has a market capitalization of $716.59 billion, a P/E ratio of 130.03, a price-to-earnings-growth ratio of 1.66 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the company posted $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.41 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.